• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore, April 8

Strides Arcolab Ltd said it has received tentative USFDA approval for its 11th new drug application for combination AIDS drug under the President's Emergency Plan for AIDS Relief . The latest approval is for a fixed dose combination of lamivudine and stavudine tablets 150 mg/30 mg under the expedited review provisions of PEPFAR. The company supplies ARV products to global procurement agencies. A release quoted Mr V.S. Iyer, CEO - India Operations, as saying, "This takes the total NDA/ANDA approvals received to 11 under the PEPFAR programme. This, combined with our pipeline of second line drugs, will make us a significant player in the quality, affordable multi-source anti-retrovirals business segment.

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line